First Patient dosed in AERIAL Trial of NKG2D CAR-T Therapy LEU011 for Solid Tumors
Filippo Petti, Chief Executive Officer, Leucid Bio, stated, “The initiation of the AERIAL trial is a significant milestone for Leucid. LEU011 has demonstrated striking anti-tumour activity preclinically, while illustrating the potential to overcome challenges in treating refractory solid tumours. It’s been fantastic to work with the team at GOSH to accelerate the development of LEU011 in the pursuit of bringing effective cell therapies to patients in need.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.